Comparison of 10 day bismuth quadruple therapy with high-dose metronidazole or levofloxacin for second-line helicobacter pylori therapy: A randomized controlled trial

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 1, 2013, Pages 222-228

  Kuo, Chao Hung ^a,b   Hsu, Ping I ^c,d   Kuo, Fu Chen ^e   Wang, Sophie S W ^a   Hu, Huang Ming ^a   Liu, Chung Jung ^a   Chuah, Seng Kee ^f   Chen, Yen Hsu ^a   Hsieh, Ming Chia ^g   Wu, Deng Chyang ^a,b   Tseng, Hui Hwa ^c  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e I SHOU UNIVERSITY   (Taiwan)

^f CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^g CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

Author keywords

CYP2C19; H. pylori; Rescue therapy

Indexed keywords

BISMUTH CITRATE; CYTOCHROME P450 2C19; ESOMEPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; TETRACYCLINE;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ANTIBIOTIC RESISTANCE; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DNA POLYMORPHISM; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; ENDOSCOPY; FATIGUE; FEMALE; FOLLOW UP; GENOTYPE; HELICOBACTER INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT COMPLIANCE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; SINGLE BLIND PROCEDURE; TASTE DISORDER; TREATMENT RESPONSE; UREA BREATH TEST; VOMITING;

ADULT; AGED; ANTI-BACTERIAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; OFLOXACIN; ORGANOMETALLIC COMPOUNDS; QUESTIONNAIRES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84871253050     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks361     Document Type: Article

References (42)

1. Malfertheiner P, Megraud F, O'Morain CA et al. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut 2012; 61: 646-64.
2. Fennerty MB, Lieberman DA, Vakil N et al. Effectiveness of Helicobacter pylori therapies in a clinical practice setting. Arch Intern Med 1999; 159: 1562-6.
3. Della Monica P, Lavagna A, Masoero G et al. Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy. Aliment Pharmacol Ther 2002; 16: 1269-75.
4. Liou JM, Lin JT, Chang CY et al. Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design. Gut 2010; 59: 572-8.
5. Gisbert JP, Bermejo MF, Infante JM et al. Levofloxacin, amoxicillin, and omeprazole as first-line triple therapy for Helicobacter pylori eradication. J Clin Gastroenterol 2009; 43: 384-5.
6. Kuo CH, Hu HM, Kuo FC et al. Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial. J Antimicrob Chemother 2009; 63: 1017-24.
7. Kim JM, Kim JS, Kim N et al. Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients. J Antimicrob Chemother 2005; 56: 965-7.
8. Hung IF, Chan P, Leung S et al. Clarithromycin-amoxicillin-containing triple therapy: a valid empirical first-line treatment for Helicobacter pylori eradication in Hong Kong? Helicobacter 2009; 14: 505-11.
9. Graham DY, Abudayyeh S, El-Zimaity HM et al. Sequential therapy using high-dose esomeprazole-amoxicillin followed by gatifloxacin for Helicobacter pylori infection. Aliment Pharmacol Ther 2006; 24: 845-50.
10. de Boer WA, Tytgat GN. The best therapy for Helicobacter pylori infection: should efficacy or side-effect profile determine our choice? Scand J Gastroenterol 1995; 30: 401-7.
11. Romano M, Cuomo A. Eradication of Helicobacter pylori: a clinical update. Med Gen Med 2004; 6: 19.
12. Wu IC, Ke HL, Lo YC et al. Evaluation of a newly developed office-based stool test for detecting Helicobacter pylori: an extensive pilot study. Hepatogastroenterology 2003; 50: 1761-5.
13. Morgner A, Labenz J, Miehlke S. Effective regimens for the treatment of Helicobacter pylori infection. Expert Opin Investig Drugs 2006; 15: 995-1016.
14. Cheng HC, Chang WL, Chen WY et al. Levofloxacin-containing triple therapy to eradicate the persistent H. pylori after a failed conventional triple therapy. Helicobacter 2007; 12: 359-63.
15. Lamouliatte H, Megraud F, Delchier JC et al. Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies. Aliment Pharmacol Ther 2003; 18: 791-7.
16. Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter 2007; 12: 275-8.
17. Miwa H, Nagahara A, Kurosawa A et al. Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection? Aliment Pharmacol Ther 2003; 17: 1545-51.
18. Wong WM, Gu Q, Chu KM et al. Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2006; 23: 421-7.
19. Megraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007; 20: 280-322.
20. Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53: 1374-84.
21. de Boer W, Driessen W, Jansz A et al. Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection. Lancet 1995; 345: 817-20.
22. de BoerWA, van Etten RJ, Lai JYet al. Effectiveness of quadruple therapy using lansoprazole, instead of omeprazole, in curing Helicobacter pylori infection. Helicobacter 1996; 1: 145-50.
23. Wu DC, Hsu PI, Wu JY et al. Sequential and concomitant therapy with four drugs is equally effective for eradication of H. pylori infection. Clin Gastroenterol Hepatol 2010; 8: 36-41.e1.
24. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006; 23: 35-44.
25. Baena Diez JM, Lopez Mompo C, Rams Rams F et al. [Efficacy of a multistep strategy for Helicobacter pylori eradication: quadruple therapy with omeprazole, metronidazole, tetracycline and bismuth after failure of a combination of omeprazole, clarithromycin and amoxicillin]. Med Clin (Barc) 2000; 115: 617-9.
26. Michopoulos S, Tsibouris P, Bouzakis H et al. Randomized study comparing omeprazole with ranitidine as anti-secretory agents combined in quadruple second-line Helicobacter pylori eradication regimens. Aliment Pharmacol Ther 2000; 14: 737-44.
27. Rokkas T, Sechopoulos P, Robotis I et al. Cumulative H. pylori eradication rates in clinical practice by adopting first- and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. Am J Gastroenterol 2009; 104: 21-5.
28. de Boer WA. Bismuth triple therapy: still a very important drug regimen for curing Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1999; 11: 697-700.
29. de Boer WA, van Etten RJ, Schneeberger PM. Four-day lansoprazolequadruple therapy in the routine treatment of Helicobacter pylori infection. Neth J Med 1998; 52: 10-5.
30. Filipec Kanizaj T, Katicic M, Skurla B et al. Helicobacter pylori eradication therapy success regarding different treatment period based on clarithromycin or metronidazole triple-therapy regimens. Helicobacter 2009; 14: 29-35.
31. Bardhan K, Bayerdorffer E, Veldhuyzen Van Zanten SJ et al. The HOMER Study: the effect of increasing the dose of metronidazole when given with omeprazole and amoxicillin to cure Helicobacter pylori infection. Helicobacter 2000; 5: 196-201.
32. van der Hulst RW, Keller JJ, Rauws EA et al. Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter 1996; 1: 6-19.
33. Giannini EG, Bilardi C, Dulbecco P et al. Can Helicobacter pylori eradication regimens be shortened in clinical practice? An open-label, randomized, pilot study of 4- and 7-day triple therapy with rabeprazole, high-dose levofloxacin, and tinidazole. J Clin Gastroenterol 2006; 40: 515-20.
34. Nwokolo CU, Lewin JF, Hudson M et al. Transmucosal penetration of bismuth particles in the human stomach. Gastroenterology 1992; 102: 163-7.
35. Hassan-Alin M, Andersson T, Bredberg E et al. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur J Clin Pharmacol 2000; 56: 665-70.
36. Dent J. Review article: pharmacology of esomeprazole and comparisons with omeprazole. Aliment Pharmacol Ther 2003; 17 Suppl 1: 5-9.
37. Hsu PI, Lai KH, Lin CK et al. A prospective randomized trial of esomeprazole-versus pantoprazole-based triple therapy for Helicobacter pylori eradication. Am J Gastroenterol 2005; 100: 2387-92.
38. Anagnostopoulos GK, Tsiakos S, Margantinis G et al. Esomeprazole versus omeprazole for the eradication of Helicobacter pylori infection: results of a randomized controlled study. J Clin Gastroenterol 2004; 38: 503-6.
39. Sheu BS, Kao AW, Cheng HC et al. Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism. Aliment Pharmacol Ther 2005; 21: 283-8.
40. Briasoulis A, Agarwal V, Pierce WJ. QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications. Cardiology 2011; 120: 103-10.
41. Wang Z, Wu S. Doxycycline-based quadruple regimen versus routine quadruple regimen for rescue eradication of Helicobacter pylori: an open-label control study in Chinese patients. Singapore Med J 2012; 53: 273-6.
42. Rimbara E, Fischbach LA, Graham DY. Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol 2011; 8: 79-88.